Join
Live feed
·
PRReleasevia Quantisnow
Senti Biosciences Inc. logo

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

ByQuantisnow·Wall Street's wire, on your screen.
SNTI· Senti Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNTI (Senti Biosciences Inc.) and more on Quantisnow.